Here’s Why uniQure (QURE) Fell in Q3

2 hours ago 1

Soumya Eswaran

Tue, January 20, 2026 astatine 8:01 AM CST 3 min read

Fred Alger Management, an concern absorption company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The US equity marketplace ended the 4th fourth connected a beardown note, with the S&P surging 2.7%, maintaining its dependable upward momentum. Investors' optimism was supported by better-than-expected firm earnings, the US Federal Reserve’s further involvement complaint easing stance, and a resilient macroeconomic backdrop. Improving clarity connected commercialized argumentation provided further support. Meanwhile, the 4th was characterized by expanding divergence beneath the scale level surface. The enthusiasm for AI concern is facing increasing doubts owed to bottlenecks, financing challenges, and uncertainty implicit its quality to make returns. The steadfast continues to observe secular trends that contiguous charismatic concern opportunities for small-cap stocks. In Q4 2025, Class A shares of the Fund outperformed the Russell 2000 Growth Index. The Utilities and Financials sectors contributed to the comparative show of the Fund successful the quarter, portion the Consumer Discretionary and Information Technology sectors detracted from performance. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Alger Small Cap Focus Fund highlighted stocks specified arsenic UniQure N.V. (NASDAQ:QURE). UniQure N.V. (NASDAQ:QURE) is simply a biotechnology institution that develops treatments for patients suffering from uncommon and different devastating diseases. The one-month instrumentality of UniQure N.V. (NASDAQ:QURE) was -8.57%, and its shares gained 62.56% of their worth implicit the past 52 weeks. On November 18, 2025, UniQure N.V. (NASDAQ:QURE) banal closed astatine $22.84 per share, with a marketplace capitalization of $1.42 billion.

Alger Small Cap Focus Fund stated the pursuing regarding UniQure N.V. (NASDAQ:QURE) successful its 4th fourth 2025 capitalist letter:

"UniQure N.V. (NASDAQ:QURE) is simply a biotechnology institution processing AMT-130, an investigational cistron therapy for Huntington’s disease—an country with nary approved disease-modifying treatments. Shares were highly volatile successful 2025, surging aft the institution reported three-year Phase 1/2 information indicating meaningfully slower illness progression—approximately 75% versus a propensity-matched outer power cohort. However, shares detracted during the 4th aft U.S. Food and Drug Administration (FDA) feedback signaled that the external-control dataset whitethorn nary longer beryllium capable arsenic superior grounds to enactment an accelerated support filing, expanding regulatory uncertainty and apt extending the timeline contempt the encouraging efficacy signal."